$EVOK
Evoke Pharma Inc

2018 Q2 Form 10-Q Financial Statement

#000156459018021043 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $920.0K $870.0K
YoY Change 5.75% 8.75%
% of Gross Profit
Research & Development $1.389M $2.018M
YoY Change -31.17% -3.7%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.306M $2.890M
YoY Change -20.19% -0.28%
Operating Profit -$2.306M
YoY Change
Interest Expense $2.903K $1.667K
YoY Change 74.15% -102.38%
% of Operating Profit
Other Income/Expense, Net $2.902K $1.264M
YoY Change -99.77% -1838.22%
Pretax Income -$2.300M -$1.630M
YoY Change 41.1% -45.12%
Income Tax
% Of Pretax Income
Net Earnings -$2.303M -$1.626M
YoY Change 41.65% -45.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.11
Diluted Earnings Per Share -$0.14 -$0.13
COMMON SHARES
Basic Shares Outstanding 15.34M
Diluted Shares Outstanding 16.43M 15.42M

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.530M $12.56M
YoY Change -48.01% 204.12%
Cash & Equivalents $6.531M $12.56M
Short-Term Investments
Other Short-Term Assets $90.00K $590.0K
YoY Change -84.75% 15.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.630M $13.14M
YoY Change -49.54% 183.19%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $10.00K
YoY Change -100.0%
Total Long-Term Assets $0.00 $20.00K
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $6.630M $13.14M
Total Long-Term Assets $0.00 $20.00K
Total Assets $6.630M $13.16M
YoY Change -49.62% 183.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $440.0K $1.120M
YoY Change -60.71% -11.11%
Accrued Expenses $820.0K $760.0K
YoY Change 7.89% 52.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.270M $1.880M
YoY Change -32.45% -69.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $4.510M
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $4.510M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.270M $1.880M
Total Long-Term Liabilities $0.00 $4.510M
Total Liabilities $1.270M $6.390M
YoY Change -80.13% 3.68%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.360M $6.770M
YoY Change
Total Liabilities & Shareholders Equity $6.630M $13.16M
YoY Change -49.62% 183.84%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$2.303M -$1.626M
YoY Change 41.65% -45.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.760M -$2.090M
YoY Change -15.79% -6.28%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.890M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.760M -2.090M
Cash From Investing Activities
Cash From Financing Activities 2.890M 0.000
Net Change In Cash 1.130M -2.090M
YoY Change -154.07% 6.09%
FREE CASH FLOW
Cash From Operating Activities -$1.760M -$2.090M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7930313
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2306096
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
2889548
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2903
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1667
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1261912
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2903
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2303193
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16425468
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
312224
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4579708
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3783030
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3431520
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7332239
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1148188
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9007071
evok Reclassification Of Warrant Liability To Equity Due To Exercise Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToExerciseOfWarrants
1399091
evok Reclassification Of Warrant Liability To Equity Due To Amendment Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToAmendmentOfWarrants
3267885
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2017Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2017Q2 evok Amount Of Dilutive Securities Change In Fair Value Of Warrants
AmountOfDilutiveSecuritiesChangeInFairValueOfWarrants
-429702
evok Amount Of Dilutive Securities Change In Fair Value Of Warrants
AmountOfDilutiveSecuritiesChangeInFairValueOfWarrants
-429702
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2303193
CY2017Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
77629
CY2017Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
80000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
50244
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6286425
CY2018Q2 evok Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
2028-02
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
387429
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
464871
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2017Q4 us-gaap Alternative Investment Measurement Input Extensible List
AlternativeInvestmentMeasurementInputExtensibleList
evok:BlackScholesOptionPricingModelMember
CY2018Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0

Files In Submission

Name View Source Status
0001564590-18-021043-index-headers.html Edgar Link pending
0001564590-18-021043-index.html Edgar Link pending
0001564590-18-021043.txt Edgar Link pending
0001564590-18-021043-xbrl.zip Edgar Link pending
evok-10q_20180630.htm Edgar Link pending
evok-20180630.xml Edgar Link completed
evok-20180630.xsd Edgar Link pending
evok-20180630_cal.xml Edgar Link unprocessable
evok-20180630_def.xml Edgar Link unprocessable
evok-20180630_lab.xml Edgar Link unprocessable
evok-20180630_pre.xml Edgar Link unprocessable
evok-ex311_7.htm Edgar Link pending
evok-ex312_10.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending